COMMUNIQUÉS West-GlobeNewswire

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026
20/01/2026
The Company enters 2026 with Multiple Phase 2 Catalysts, AI-enabled drug development strategy, and regulatory optionality as SKNJCT-003 study approaches database lock, topline clinical data readout and partnering [...]
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
20/01/2026
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced that it has decided to postpone the previously announced effective date of its [...]
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
20/01/2026
Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injury Participants to include people with Long COVID who [...]
Avacta Announces Year-end Trading Update
20/01/2026
LONDON and PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION ® , a tumor-activated oncology delivery platform, has [...]
Genvor, Inc. to Present at the 3rd Annual DealFlow Discovery Conference
20/01/2026
Woodland, CA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTC: GNVR), a biotechnology company pioneering AI-accelerated peptide technology for sustainable agriculture, today announced that it will participate in the [...]
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
20/01/2026
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway into the second [...]
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
20/01/2026
VANCOUVER, British Columbia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class [...]
NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei
20/01/2026
Executive Chairman of the Board, Fu Wei, informed the Company of his intent to purchase up to $5,000,000 of the Company’s American Depository Shares (ADSs) ROCKVILLE, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge [...]
Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
20/01/2026
Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following longer 8-week treatment 75% of soquelitinib patients achieved EASI 75, 25% achieved EASI 90 and [...]
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting
20/01/2026
sNDA submission supports the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI ® Submission timeline supports potential approval of IGALMI ® [...]
BPGbio Receives FDA Orphan Drug Designation for BPM31510 for the Treatment of Primary CoQ10 Deficiency
20/01/2026
BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- BPGbio, Inc ., a leading biology-first, AI-powered clinical-stage biopharma company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug [...]
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
20/01/2026
MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides an update on its commercial and operational performance for the quarter [...]
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
20/01/2026
Primary Safety Endpoint Demonstrated to Date; Top-Line Efficacy Data Expected in Q3 2026 Ramat Gan, Israel, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage [...]
smartbax in-licenses lead antibacterial compound targeting Gram-negative infections from Aicuris
20/01/2026
Munich, Germany, Jan. 20, 2026 (GLOBE NEWSWIRE) -- smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the in-licensing of a new compound class from [...]
Levicept Announces FDA Acceptance of IND Application for LEVI-04, a Potentially Disease-Modifying Treatment for Osteoarthritis
20/01/2026
SANDWICH, United Kingdom, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the US Food [...]
Nxera Pharma Establishes Metabolic Advisory Council to Advance Next-Generation Therapies for Obesity and Metabolic Disorders
20/01/2026
Council brings together leading global scientific and clinical experts in metabolic diseases to guide development of Nxera’s expanding proprietary pipeline Tokyo, Japan and Cambridge, UK, 20 January 2026 – Nxera Pharma [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
20/01/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 20 January 2026 at 08.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations
20/01/2026
Press Release Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations January 20, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124 [...]
Nicox annonce sa participation à des congrès au premier semestre 2026 et la présentation prochaine de données scientifiques
20/01/2026
Communiqué de presse Nicox annonce sa participation à des congrès au premier semestre 2026 et la présentation prochaine de données scientifiques 20 janvier 2026 – publication à 7H30 Sophia Antipolis, France Nicox SA ( [...]

Pages